Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$10.51
$10.51
$3.75
$10.73
$769.27M-0.3219,508 shsN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$27.84
-2.6%
$30.77
$24.10
$62.53
$2.68B0.33767,621 shs891,936 shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$42.96
-1.8%
$43.85
$19.44
$53.27
$2.85B2.18557,010 shs393,426 shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00%0.00%0.00%0.00%0.00%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-2.62%-10.16%-5.43%-17.54%-47.59%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-1.81%-6.18%-3.53%+21.77%-7.01%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%+1.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.3269 of 5 stars
3.40.00.03.72.12.50.0
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.5763 of 5 stars
4.63.00.00.03.42.50.0
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00
N/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.80
Moderate Buy$69.50149.64% Upside
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.10
Buy$59.1137.60% Upside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CNVY, KYMR, CRNX, and MOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/30/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$60.00
7/15/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/10/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$36.00
7/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$70.00
6/27/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
6/27/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$59.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $60.00
6/25/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$64.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$337.60M2.28$0.46 per share22.90$7.35 per share1.43
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$1.04M2,506.40N/AN/A$14.29 per share1.95
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$47.07M59.43N/AN/A$12.90 per share3.33
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
-$9.98M-$0.10N/A25.63N/A-1.90%0.08%0.05%N/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/7/2025 (Estimated)
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A

Latest CNVY, KYMR, CRNX, and MOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$1.13N/AN/AN/A$0.52 millionN/A
8/6/2025Q2 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.84N/AN/AN/A$17.37 millionN/A
5/9/2025Q1 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million
5/8/2025Q1 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
N/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.50
2.20
1.60
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
22.53
22.53
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
8.49
8.49
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
85.28%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
MorphoSys AG stock logo
MOR
MorphoSys
18.38%

Insider Ownership

CompanyInsider Ownership
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
6.20%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
4.60%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
16.01%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
3,80073.19 million68.66 millionNot Optionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
21093.63 million89.32 millionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17065.12 million54.69 millionOptionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable

Recent News About These Companies

Novartis to shut MorphSys sites amid pelabresib delay
Novartis sheds MorphoSys staff, sites after pelabresib delay
Novartis shutters MorphoSys sites, lays off staff
Novartis raises mid-term sales guidance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Convey Health Solutions stock logo

Convey Health Solutions NYSE:CNVY

Convey Health Solutions Holdings, Inc. provides technology enabled solutions and advisory services to assist its clients with workflows across product developments, sales, member experience, clinical management, core operations, and business intelligence and analytics. It operates through two segments, Technology Enabled Solutions and Advisory Services. The Technology Enabled Solutions segment offers technology solutions through web-based customizable application that is used to identify, track, and administer contractual services, or benefits provided under a client's plan to its Medicare and Medicaid beneficiaries. It also provides analytics over healthcare data to capture and assess gaps in risk documentation, quality, clinical care, and compliance. The company also offers health plan management, data analytics, supplemental benefit, advisory, and software services. The Advisory Services segment offers sales and marketing strategies, provider network strategies, compliance, star ratings, quality, clinical, pharmacy, analytics, and risk adjustment. It serves government sponsored, medicare advantage, medicare, as well as pharmacy benefits managers. The company was founded in 2001 and is headquartered in Fort Lauderdale, Florida. Convey Health Solutions Holdings, Inc. is a former subsidiary of TPG Cannes Aggregation, L.P.

Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$27.84 -0.75 (-2.62%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$27.82 -0.02 (-0.05%)
As of 08/1/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$42.96 -0.79 (-1.81%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$42.92 -0.04 (-0.09%)
As of 08/1/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 08/1/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.